Hypertension
EuroPCR 2014: Looking for hope for renal denervation
Amid the hand-wringing and back-pedaling surrounding renal denervation, some physicians are still looking for ways to use the technology to treat patients with hypertension.
EuroPCR 2014: St. Jude touts EnligHTN data amid renal denervation backlash
EuroPCR 2014: Docs say renal denervation ads are putting ‘marketing before science’
Attendees at this year’s EuroPCR conference in Paris cast a wary eye on medical device makers’ efforts to promote renal denervation in treatment of hypertension, taking to Twitter to note and sometimes chide companies for putting "marketing before science."
Device makers take big writedowns on renal denervation
Bakris: Symplicity-3 a prologue for renal denervation | MassDevice.com On Call
Rox Medical closes enrollment in hypertension ‘stent’ trial
Rox Medical said it closed enrollment in a 100-patient clinical trial of its Rox Coupler device, designed to treat hypertension by connecting the femoral artery and the femoral vein.
CEO Rodney Brenneman told MassDevice.com that Rox Medical, a Stanford spinout established in 2004 to pursue several indications including chronic obstructive lung disease and heart failure, noticed a dramatic effect on high blood pressure in COPD patients implanted with the device.
Hypertension: Docs turn on renal denervation | MassDevice.com On Call
MASSDEVICE ON CALL — A group of cardiologists is taking a hard stance against renal denervation, calling for medical device manufacturers to stop selling the technology as a treatment for hypertension.
ACC 2014: Conflicts in renal denervation, competition in valves
The American College of Cardiology’s annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic’s (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.